Amorfix Life Sciences signs sale and distribution agreement with Cedarlane Laboratories

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, announced today that it has signed an agreement with Cedarlane Laboratories for the sale and distribution of Amorfix's proprietary antibodies and reagents.

"Amorfix has developed the world's most sensitive diagnostic assays for variant Creutzfeldt-Jakob Disease (vCJD) and for aggregated Abeta, the hallmark of Alzheimer's Disease (AD). Consequently, we have received numerous inquiries from investigators involved in protein misfolding studies for our reagents," said Dr. George Adams, CEO of Amorfix. "By making these reagents accessible, we offer the research community the opportunity to find new applications for these high-quality antibodies that have demonstrated their superior sensitivity and specificity in our detection assays."

Amorfix products offered for research purposes only through Cedarlane include:

- Antibody to a Disease Specific Epitope (DSE) on the misfolded superoxide dismutase-1 (SOD1) protein, implicated in Amyotrophic Lateral Sclerosis (ALS) - Cedarlane catalogue number CLPN40023. - Antibodies for the detection of aggregated beta-amyloids, targeting the C-terminus and N-terminus regions - Cedarlane catalogue numbers CLPN40018, CLPN40027 and CLPN40028. These antibodies are components of the Amorfix A4 test used for early detection of aggregated Abeta in transgenic mouse models of AD. - The highest purity 3F4 prion detection antibody available in the market - Cedarlane catalogue number CLPN40020. - Peroxynitrite solution for nitrating and oxidizing amino acid side chains - Cedarlane catalogue number CLPN40015. Peroxynitrite is currently used in the Epitope Protection assay for modifying epitopes on the prion protein.




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Unusual Zika virus-specific antibody exhibits ultrapotent neutralization